Insmed Non Current Assets Total from 2010 to 2024

INSM Stock  USD 69.61  1.06  1.50%   
Insmed Non Current Assets Total yearly trend continues to be very stable with very little volatility. Non Current Assets Total are likely to grow to about 420.8 M this year. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
2000-03-31
Previous Quarter
391.9 M
Current Value
403.1 M
Quarterly Volatility
126.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Insmed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Insmed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.1 M, Interest Expense of 85.8 M or Total Revenue of 320.5 M, as well as many indicators such as Price To Sales Ratio of 13.55, Dividend Yield of 0.0 or Days Sales Outstanding of 47.02. Insmed financial statements analysis is a perfect complement when working with Insmed Valuation or Volatility modules.
  
Check out the analysis of Insmed Correlation against competitors.

Latest Insmed's Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Insmed Inc over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Insmed's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Insmed's overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Insmed Non Current Assets Total Regression Statistics

Arithmetic Mean167,812,923
Geometric Mean90,727,315
Coefficient Of Variation91.47
Mean Deviation128,612,955
Median72,603,000
Standard Deviation153,504,876
Sample Variance23563.7T
Range420.2M
R-Value0.89
Mean Square Error5311.9T
R-Squared0.79
Slope30,521,499
Total Sum of Squares329892.5T

Insmed Non Current Assets Total History

2024420.8 M
2023400.8 M
2022383.1 M
2021406.5 M
2020173.3 M
2019187.1 M
201885.6 M

About Insmed Financial Statements

Insmed investors utilize fundamental indicators, such as Non Current Assets Total, to predict how Insmed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Assets Total400.8 M420.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Insmed Inc is a strong investment it is important to analyze Insmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insmed's future performance. For an informed investment choice regarding Insmed Stock, refer to the following important reports:
Check out the analysis of Insmed Correlation against competitors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.55)
Revenue Per Share
2.206
Quarterly Revenue Growth
0.182
Return On Assets
(0.26)
Return On Equity
(8.91)
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.